The estimated Net Worth of Biotech Fund I, L.P.Israel ... is at least $554 millier dollars as of 7 February 2024. Biotech Israel owns over 27,847,159 units of Ayala Pharmaceuticals stock worth over $554,356 and over the last few years Biotech sold ADXS stock worth over $0.
Sign up
Biotech Israel ADXS stock SEC Form 4 insiders trading
Biotech has made over 2 trades of the Ayala Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Biotech exercised 27,847,159 units of ADXS stock worth $11,138,864 on 7 February 2024.
The largest trade Biotech's ever made was exercising 27,847,159 units of Ayala Pharmaceuticals stock on 7 February 2024 worth over $11,138,864. On average, Biotech trades about 7,291,219 units every 28 days since 2023. As of 7 February 2024 Biotech still owns at least 27,717,808 units of Ayala Pharmaceuticals stock.
You can see the complete history of Biotech Israel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Ayala Pharmaceuticals
Over the last 21 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C.... et Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.
What does Ayala Pharmaceuticals do?
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
What does Ayala Pharmaceuticals's logo look like?
Complete history of Biotech Israel stock trades at Ayala Pharmaceuticals
Ayala Pharmaceuticals executives and stock owners
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Kenneth A. Berlin J.D.,
Pres, Interim CFO, CEO & Director -
Kenneth Berlin,
President, Chief Executive Officer, Interim Chief Financial Officer, Director -
Andres Gutierrez,
Chief Medical Officer and Executive Vice President -
Dr. Andres A. Gutierrez M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Roni Appel,
Independent Director -
David Sidransky,
Independent Chairman of the Board -
James Patton,
Independent Non-Executive Vice Chairman of the Board -
Tim McCarthy,
Investor Relations -
Samir Khleif,
Independent Director -
Richard Berman,
Independent Director -
Igor Gitelman CPA, CPA, M.B.A., MBA,
Chief Accounting Officer & VP of Fin. -
Gregory T. Mayes,,
Chief Operating Officer -
Robert J. Spiegel,
Director -
Robert Petit,
Chief Scientific Officer -
Sara Bonstein,
Chief Financial Officer -
Thomas J Mckearn,
Director -
Thomas J Ridge,
Director -
Murray A Goldberg,
Director -
Biotech Fund I, L.P.Israel ...,
-
Capital Partners Gp, L.L.C....,
-
Anthony A Lombardo,
Interim CEO -
Molly Henderson,
Executive Vice President & CFO -
Fredrick D Cobb,
Vice President Finance -
John F Rothman,
VP of Clinical Development -
David J Mauro,
Chief Medical Officer -
Daniel J. O'connor,
SVP, Legal & Business Dev Off -
Thomas A Moore,
Director -
Christy Lee French,
Exec. Dir. of Medical Affairs -
Mark J Rosenblum,
Chief Financial Officer -
Biotech Fund I, L.P.Israel ...,
-
Growth Fund Limited Partner...,
10% owner -
Vered Bisker Leib,
Director